Tirzepatide
Dual GIP/GLP-1 agonist backed by one of the most robust bodies of clinical evidence for weight and glycemic control.
Tirzepatide (LY3298176) is a dual agonist of the GIP and GLP-1 receptors. This dual activation enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces food intake — a mechanism studied extensively across the SURMOUNT and SURPASS trial programs.
Benefits studied in research
- Studied for its effect on body weight reduction, with mean decreases of ~16% to ~22.5% depending on dose in the phase 3 SURMOUNT-1 trial at 72 weeks.
- Investigated for its action on body composition, with a proportionally greater reduction in fat mass than in lean mass.
- Evaluated for its effect on glycemic control and HbA1c reduction in type 2 diabetes models.
- Analyzed for its favorable impact on cardiometabolic markers such as blood pressure and lipid profile in controlled trials.
Key data
- Class
- Dual peptide agonist
- Targets
- GLP-1 · GIP
- Status
- Phase 3 completed (research)
- Weight reduction under study
- ~16–22.5% at 72 wks (SURMOUNT-1)
- Storage
- −20 °C lyophilized · 4 °C reconstituted
Scientific backing
Peer-reviewed publications on the molecule. Research references, not indications for use.
Reconstitution calculator
Adjust the values to plan your protocol. The vial's mg sync with the size you select above.
Calculation tool for laboratory planning (RUO). An insulin U-100 syringe has 100 units = 1 ml. Not a dosing recommendation.
Frequently asked questions
Tirzepatide acts on two receptors (GIP/GLP-1) and has completed phase 3; Retatrutide adds the glucagon receptor and is at an earlier research stage, with larger weight reductions in phase 2. You can view them side by side in the comparison tool.
Semaglutide is a single GLP-1 agonist; Tirzepatide adds the GIP pathway, which in studies is associated with greater effects on weight and glycemia.
